Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab with Chemoradiotherapy for Anal Canal Squamous Carcinoma
NCT05374252Phase 3Recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- May 2022
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in anal canal squamous cell carcinoma (SCCA), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Started May 2022; status: recruiting.
02
Drugs
sintilimab
03
Conditions
anal canal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT05374252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05374252.